{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-036402","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.165682+00:00","generated_at":"2026-06-15T22:26:20.696149+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"INmune Bio Q1 net loss $6.5M; cash $51M; advances DN-TNF and INKmune trials","bullets":["Net loss $6.5M vs $6.9M YoY; R&D $4.1M, G&A $2.3M.","Cash and equivalents $51.0M at March 31, 2023; 17.9M shares outstanding.","FDA provides clear pathway to lift clinical hold on AD Phase 2 by year-end.","IND filed for INKmune in mCRPC; Phase 1 in MDS/AML enrolling at three sites.","Top-line XPro Alzheimer's results expected 2H 2024; NIH-funded depression trial pending FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-036402","json":"https://secwatch.observer/filing/0001213900-23-036402.json","markdown":"https://secwatch.observer/filing/0001213900-23-036402.md","text":"https://secwatch.observer/filing/0001213900-23-036402.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390023036402/0001213900-23-036402-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390023036402/ea177977-8k_inmunebio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T22:26:20.696149+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7ffa53f5e2e038cb25b193bfd252b936020034b2","claim":"Inmune Bio, Inc. reported the quarter ended March 31, 2023 results: net income approximately $6.5 million.","evidence_excerpt":"Net loss attributable to common stockholders for the quarter ended March 31, 2023 was approximately $6.5 million, compared to approximately $6.9 million during the quarter ended March 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390023036402/0001213900-23-036402-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Net income","value":"approximately $6.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}